Fiscal Period | 2024 |
---|---|
Period End Date | Sep 23 |
Revenue | 1031.40 |
Total Revenue | 1031.40 |
Costof Revenue Total | 215.80 |
Gross Profit | 815.60 |
Selling/ General/ Admin Expenses Total | 122.40 |
Depreciation/ Amortization | 43.60 |
Other Operating Expenses Total | 235.20 |
Total Operating Expense | 617.00 |
Operating Income | 414.40 |
Interest Inc( Exp) Net- Non- Op Total | -42.00 |
Other Net | 29.40 |
Net Income Before Taxes | 439.60 |
Provisionfor Income Taxes | 70.60 |
Net Income After Taxes | 369.00 |
Minority Interest | 0.00 |
Net Income Before Extra Items | 369.00 |
Net Income | 369.00 |
Income Availableto Com Excl Extra Ord | 369.00 |
Income Availableto Com Incl Extra Ord | 369.00 |
Diluted Net Income | 369.00 |
Diluted Weighted Average Shares | 17.91 |
Diluted EPS Excluding Extra Ord Items | 20.60 |
DPS- Common Stock Primary Issue | 1.25 |
Diluted Normalized EPS | 20.60 |
Natco Pharma Dividend | Natco Pharma Bonus | Natco Pharma News | Natco Pharma AGM | Natco Pharma Rights | Natco Pharma Splits | Natco Pharma Board Meetings | Natco Pharma Key Metrics | Natco Pharma Shareholdings | Natco Pharma Profit Loss | Natco Pharma Balance Sheet | Natco Pharma Cashflow | Natco Pharma Q1 Results | Natco Pharma Q3 Results | Natco Pharma Q4 Results
Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks